Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
Copyright © 2021. Published by Elsevier Inc..
BACKGROUND: The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by DLBCL subtype to determine the effects of DLBCL subtypes on efficacy and tolerability of selinexor.
PATIENTS AND METHODS: Data from 134 patients in SADAL were analyzed by DLBCL subtypes for overall response rate (ORR), overall survival (OS), duration of treatment response, progression-free survival, and adverse events rate.
RESULTS: ORR in the entire cohort was 29.1%, and similar in patients with germinal center (GCB) versus non-GCB DLBCL (31.7% vs. 24.2%, P = 0.45); transformed DLBCL showed a trend towards higher ORR than de novo DLBCL: 38.7% vs. 26.2% (P = 0.23). Despite similar prior treatment regimens and baseline characteristics, patients with DLBCL and normal C-MYC/BCL-2 protein expression levels had a significantly higher ORR (46.2% vs.14.8%, P = 0.012) and significantly longer OS (medians 13.7 vs. 5.1 months, hazard ratio 0.43 [95% CI, 0.23-0.77], P = 0.004) as compared with those whose DLBCL had C-MYC and BCL-2 overexpression. Among patients who had normal expression levels of either C-MYC or BCL-2 and baseline hemoglobin levels ≥ 10g/dL, ORR was 51.5% (n = 47), with median OS of 15.5 months and median PFS of 4.6 months. Similar rates of adverse events were noted in all subgroups.
CONCLUSIONS: Overall, single agent oral selinexor showed strong responses in patients with limited treatment alternatives regardless of germinal center B-cell type or disease origin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 22(2022), 1 vom: 04. Jan., Seite 24-33 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 31.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clml.2021.07.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330358057 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330358057 | ||
| 003 | DE-627 | ||
| 005 | 20231225211121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2021.07.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM330358057 | ||
| 035 | |a (NLM)34493477 | ||
| 035 | |a (PII)S2152-2650(21)00299-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Casasnovas, Rene-Olivier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by DLBCL subtype to determine the effects of DLBCL subtypes on efficacy and tolerability of selinexor | ||
| 520 | |a PATIENTS AND METHODS: Data from 134 patients in SADAL were analyzed by DLBCL subtypes for overall response rate (ORR), overall survival (OS), duration of treatment response, progression-free survival, and adverse events rate | ||
| 520 | |a RESULTS: ORR in the entire cohort was 29.1%, and similar in patients with germinal center (GCB) versus non-GCB DLBCL (31.7% vs. 24.2%, P = 0.45); transformed DLBCL showed a trend towards higher ORR than de novo DLBCL: 38.7% vs. 26.2% (P = 0.23). Despite similar prior treatment regimens and baseline characteristics, patients with DLBCL and normal C-MYC/BCL-2 protein expression levels had a significantly higher ORR (46.2% vs.14.8%, P = 0.012) and significantly longer OS (medians 13.7 vs. 5.1 months, hazard ratio 0.43 [95% CI, 0.23-0.77], P = 0.004) as compared with those whose DLBCL had C-MYC and BCL-2 overexpression. Among patients who had normal expression levels of either C-MYC or BCL-2 and baseline hemoglobin levels ≥ 10g/dL, ORR was 51.5% (n = 47), with median OS of 15.5 months and median PFS of 4.6 months. Similar rates of adverse events were noted in all subgroups | ||
| 520 | |a CONCLUSIONS: Overall, single agent oral selinexor showed strong responses in patients with limited treatment alternatives regardless of germinal center B-cell type or disease origin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DLBCL subtypes | |
| 650 | 4 | |a De novo and transformed DLBCL | |
| 650 | 4 | |a Relapsed/refractory DLBCL | |
| 650 | 4 | |a Salvage therapy | |
| 650 | 4 | |a Treatment response | |
| 650 | 4 | |a XPO1 | |
| 650 | 7 | |a Hydrazines |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a selinexor |2 NLM | |
| 650 | 7 | |a 31TZ62FO8F |2 NLM | |
| 700 | 1 | |a Follows, George |e verfasserin |4 aut | |
| 700 | 1 | |a Zijlstra, Josee M |e verfasserin |4 aut | |
| 700 | 1 | |a Vermaat, Joost S P |e verfasserin |4 aut | |
| 700 | 1 | |a Kalakonda, Nagesh |e verfasserin |4 aut | |
| 700 | 1 | |a Choquet, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Neste, Eric Van Den |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Thieblemont, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a la Cruz, Fatima De |e verfasserin |4 aut | |
| 700 | 1 | |a Kuruvilla, John |e verfasserin |4 aut | |
| 700 | 1 | |a Hamad, Nada |e verfasserin |4 aut | |
| 700 | 1 | |a Jaeger, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Caimi, Paolo F |e verfasserin |4 aut | |
| 700 | 1 | |a Gurion, Ronit |e verfasserin |4 aut | |
| 700 | 1 | |a Warzocha, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Bakhshi, Sameer |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho, Juan-Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Schuster, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Egyed, Miklos |e verfasserin |4 aut | |
| 700 | 1 | |a Offner, Fritz |e verfasserin |4 aut | |
| 700 | 1 | |a Vassilakopoulos, Theodoros P |e verfasserin |4 aut | |
| 700 | 1 | |a Samal, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Ku, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Chamoun, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Jatin |e verfasserin |4 aut | |
| 700 | 1 | |a Canales, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Maerevoet, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Shacham, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Kauffman, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Goy, Andre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 22(2022), 1 vom: 04. Jan., Seite 24-33 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g day:04 |g month:01 |g pages:24-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2021.07.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |b 04 |c 01 |h 24-33 | ||